Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06658002 · ClinicalTrials.gov registry record · Phase 3
Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A
A Phase 3 study of Corneal Ulcer and Fungal Keratitis, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT06658002 is a Phase 3 study of Corneal Ulcer and Fungal Keratitis that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 150 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06658002, a Phase 3 study of Corneal Ulcer and Fungal Keratitis, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with standard of care topical Natamycin treatment improves vision outcomes in patients with fungal keratitis.
Conditions Studied
Interventions
- DRUG Cyclosporine A
- OTHER Placebo Comparator: Placebo
Study Locations (2)
California
- University of California, San Farncisco - San Francisco
Tamil Nadu
- Aravind Eye Institute - Pondicherry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-09-01 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06658002
The ClinicalTrials.gov registry entry for NCT06658002 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Corneal Ulcer appearing as the primary indexed condition, and to 2 interventions - of which Cyclosporine A is the first listed.
NCT06658002 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Tamil Nadu.
Frequently Asked Questions
What is clinical trial NCT06658002 about?
NCT06658002 is a clinical study titled "Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A". The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with standard of care topical Natamycin treatment improves vision outcomes in patients with fungal keratitis.
What is the current status of trial NCT06658002?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2025-09-01. Estimated completion is 2027-09-01.
What conditions does trial NCT06658002 study?
This clinical trial studies the following conditions: Corneal Ulcer, Fungal Keratitis.
What interventions are being tested in trial NCT06658002?
The interventions under investigation include: Cyclosporine A (DRUG), Placebo Comparator: Placebo (OTHER).
Who is sponsoring clinical trial NCT06658002?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06658002 being conducted?
This trial has 2 study locations across California, Tamil Nadu. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corneal Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.